Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

American CryoStem Announces Breakthroughs in the Expansion and Lineage-Specific Differentiations of ADSCs

Published: Monday, April 28, 2014
Last Updated: Monday, April 28, 2014
Bookmark and Share
Company's ACS Laboratory division has completed its quarterly laboratory R&D program ahead of schedule, yielding new intellectual property and positive results for expanding and differentiating adipose-derived stem cells.

Breakthroughs in American CryoStem’s proprietary cell culture medium (ACSelerate™) and culturing methodology have enabled the Company to accelerate the robust cellular expansion and rapid differentiation of ADSCs to adipocytes (fat cells), chondrocytes (cartilage-producing cells) and osteocytes (bone-producing cells). Working with its patented media technologies, the Company has been able to accelerate early adipocyte formation to within 24 to 72 hours; to produce chondrocyte filaments contracting into early cartilaginous tissue within 48 to 72 hours; and to form heavily mineralized, trabecular bone tissue within 11 days -- processes that typically require several weeks to complete.

Dr. Michael Moeller, Chief Scientist at American CryoStem, stated. “The development of rapid, efficient and reproducible methods of differentiating distinct mature cells from adipose tissue will prove invaluable to the Regenerative Medicine industry. The ability to quickly grow large numbers of ADSCs from patient samples and to rapidly differentiate them into distinct lineages will open the door to multiple therapeutic and regenerative approaches supported in our ongoing university and corporate collaborations.”

“We are pleased with our laboratory’s success in developing and improving the Company’s products for research and therapeutic applications. This improvement is significant to the industry in that rapid differentiation of harvested adipose derived stem cells can reduce the lead time for proper and complete identification of these cells from weeks to just days,” added Anthony Dudzinski, American CryoStem’s COO. Continuing, he noted, “Our goal is to improve and accelerate the movement of cellular therapies from the lab to the patient.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

American CryoStem Licenses its ATGRAFT Technologies with HIT
Company enters into an agreement to license its ATGRAFT(TM) adipose tissue processing and storage technologies with Health Innovative Technology Corporation.
Wednesday, July 02, 2014
American CryoStem, Rutgers File Joint Patent
Combined technologies create basis for joint development of multi-functional nanotechnology platforms.
Thursday, April 10, 2014
American CryoStem Joins Alliance for Regenerative Medicine
The company’s decision to join ARM was based on the alignment of its ongoing mission to offer the highest quality products and services to help accelerate the regenerative medicine industry and ARM's support of policy efforts toward safe and reliable cellular products.
Thursday, February 09, 2012
American CryoStem Completes Cell Processing for Clinical Study
The study involves researching the regenerative function of participant's adipose derived mesenchymal stem cells and their ability to heal skin wounds.
Tuesday, February 07, 2012
American CryoStem Launches New Consumer Website Design
The new website is a sophisticated online destination showcasing the Company's branding and marketing of its core "Collect Process and Store" consumer stem cell service.
Friday, January 20, 2012
Scientific News
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!